Literature DB >> 8782354

Immunisation of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen.

L P Londoño1, S Chatfield, R W Tindle, K Herd, X M Gao, I Frazer, G Dougan.   

Abstract

Live vaccines based on BRD509, an attenuated S. typhimurium (aroA, aroD) strain, were constructed that directed the expression of hepatitis B core antigen particles (HBcAg) (BRD969) or HBcAg harbouring human papillomavirus type 16 E7 protein sequences (BRD974), under the control of the in vivo inducible nirB promoter. These strains were used to orally or intravenously immunise different inbred mouse strains and humoral, secretory and cellular anti-E7 and anti-HBcAg responses were monitored. Both BRD969 and BRD974 induced anti-HBcAg humoral IgG responses following oral or intravenous immunisation of B10 mice, although responses were higher in BRD969 immunised animals. IgG subclass analysis revealed a predominantly IgG2a response in these animals. BRD974, but not BRD969, induced anti-E7 humoral IgG responses. Anti-HBcAg (BRD969 and BRD974) and anti-E7 (BRD974) IgA responses were detected in the intestines of orally immunised mice. Anti-Salmonella but not anti-HBcAg or anti-E7 T helper cell responses were detected in mice immunised with BRD509, BRD969 and BRD974. Thus Salmonella vaccine strains can be used to efficiently deliver HBcAg and E7 epitopes to the mucosal and systemic immune systems.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8782354     DOI: 10.1016/0264-410x(95)00216-n

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Production of human papillomavirus type 16 E7 protein in Lactococcus lactis.

Authors:  L G Bermúdez-Humarán; P Langella; A Miyoshi; A Gruss; R Tamez Guerra; Roberto Montes de Oca-Luna; Yves Le Loir
Journal:  Appl Environ Microbiol       Date:  2002-02       Impact factor: 4.792

2.  Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.

Authors:  D W Liu; Y P Tsao; J T Kung; Y A Ding; H K Sytwu; X Xiao; S L Chen
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

Authors:  D Nardelli-Haefliger; R B Roden; J Benyacoub; R Sahli; J P Kraehenbuhl; J T Schiller; P Lachat; A Potts; P De Grandi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

4.  Comparison of a regulated delayed antigen synthesis system with in vivo-inducible promoters for antigen delivery by live attenuated Salmonella vaccines.

Authors:  Shifeng Wang; Yuhua Li; Huoying Shi; Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

5.  Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth.

Authors:  D W Liu; Y P Tsao; C H Hsieh; J T Hsieh; J T Kung; C L Chiang; S J Huang; S L Chen
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.

Authors:  Mi Suk Kim; Jeong-Im Sin
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

7.  Mucosal and systemic immune responses to chimeric fimbriae expressed by Salmonella enterica serovar typhimurium vaccine strains.

Authors:  H Chen; D M Schifferli
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

8.  Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice.

Authors:  Yi-Fang Chen; Chih-Wei Lin; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Use of stabilized luciferase-expressing plasmids to examine in vivo-induced promoters in the Vibrio cholerae vaccine strain CVD 103-HgR.

Authors:  Cara E Morin; James B Kaper
Journal:  FEMS Immunol Med Microbiol       Date:  2009-07-01

10.  Oral vaccination against tetanus: comparison of the immunogenicities of Salmonella strains expressing fragment C from the nirB and htrA promoters.

Authors:  M Roberts; J Li; A Bacon; S Chatfield
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.